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Abstract
Background: We previously developed a simple method termed HpaII-McrBC PCR (HM-PCR) to discriminate allelic
methylation status of the genomic sites of interest, and successfully applied it to a comprehensive analysis of CpG
islands (CGIs) on human chromosome 21q. However, HM-PCR requires 200 ng of genomic DNA to examine one
target site, thereby precluding its application to such samples that are limited in quantity.
Findings: We developed HpaII-McrBC whole-genome-amplification PCR (HM-WGA-PCR) that uses whole-genome-
amplified DNA as the template. HM-WGA-PCR uses only 1/100th the genomic template material required for HM-
PCR. Indeed, we successfully analyzed 147 CGIs by HM-WGA-PCR using only ~300 ng of DNA, whereas previous
HM-PCR study had required ~30 μg. Furthermore, we confirmed that allelic methylation status revealed by HM-
WGA-PCR is identical to that by HM-PCR in every case of the 147 CGIs tested, proving high consistency between
the two methods.
Conclusions: HM-WGA-PCR would serve as a reliable alternative to HM-PCR in the analysis of allelic methylation
status when the quantity of DNA available is limited.
Findings
Background
The Human Genome Project has contributed to pro-
gress in various research fields including epigenetics (i.
e., the study of the phenomena that regulate gene
expression without alteration of genomic sequences).
Various posttranslational modifications of histones and
DNA methylation represent typical epigenetic events [1].
Most CpG dinucleotides in the mammalian genome are
modified by a methyl group at the C5-position of the
cytosine. CpG dinucleotides occur in mammalian gen-
omes less frequently than would be expected from the
GC-content of DNA, because methylated CpG fre-
quently converts to TpG, while unmethylated CpG does
not [2]. However, there are CpG-rich regions, called
CpG islands (CGIs), in the mammalian genome [3]. It is
thought that CGIs are able to keep their CpG-rich
sequences, because they generally escape methylation
[4]. CGIs often lie in the promoter regions of house-
keeping genes and are occasionally found associated
with tissue-specific genes [3]. However, CGIs on the ×
chromosomes of females and those around imprinted
genes are subject to monoallelic methylation in a ran-
dom and a parent of origin-dependent manner, respec-
tively [5]. Aberrant methylation is also frequently
observed in various types of cancer cell [6].
DNA methylation contributes to the regulation of
gene expression, as well as to the suppression of parasi-
tic sequences, inactivation of the × chromosome in
females, genomic imprinting, and maintenance of chro-
mosome stability. Thus, it is important to profile DNA
methylation at human gene promoters in each type of
adult tissue and during different stages of human devel-
opment [7]. For this purpose, we previously developed a
method called HpaII-McrBC P C R( H M - P C R )t h a tf u l l y
exploits reference sequence data to reveal allelic methy-
lation status of genomic sites of interest [8]. It has been
successfully applied to comprehensive analyses of allelic
methylation status of CGIs on human chromosomes
21q [8] and 11q [9] in peripheral blood cells as well as
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any medium, provided the original work is properly cited.181 alternative promoters of 61 human genes in five dif-
ferent tissues [10]. Our analysis of chromosome 21q not
only provided one of the first lines of evidence for CGI
methylation in normal tissues, but reported a first case
of nonimprinted, sequence-dependent allele-specific
methylation (ASM) [8]. The latter finding was followed
by a series of recent studies that uncover a wide occur-
rence of SNP/haplotype-dependent ASM often asso-
ciated with allele-specific expression of nearby genes
[11,12]. These findings underscore the importance of
analyzing allelic methylation status to reveal both
imprinted and nonimprinted forms of ASM.
In this context, it should be noted that HM-PCR
serves as a much simpler assay for ASM than any other
ones including bisulfite conversion. It, however, requires
200 ng of genomic DNA to examine the methylation
status of one target site. Accordingly, HM-PCR is not
suitable for a comprehensive analysis of allelic methyla-
tion status when the quantity of sample DNA is limited.
To overcome this problem, we integrated a method
for whole genome amplification (WGA) with HM-PCR
to develop HM-WGA-PCR. This method allows us to
examine allelic methylation status using only 1/100th
the amount of DNA required for the original HM-PCR
with comparable accuracy.
Methods
Preparation of genomic DNA
Normal human genomic DNA from peripheral blood
cells was obtained from Novagen. To purify genomic
DNA, the DNA was incubated in 1 M NaCl solution
overnight at 37°C and subjected to phenol-chloroform
extraction. The DNA was recovered by standard ethanol
precipitation and dissolved in TE (10 mM Tris-HCl (pH
8.0), 1 mM EDTA). For this human genome research,
we have received ethical approval from Kanazawa
University Ethics Committee (approval number: 231).
HM-WGA-PCR
Genomic DNA (500 ng) was digested with 50 U of
HpaII, HhaI, MspI( T a K a R a ) ,o rMcrBC (New England
Biolabs) overnight at 37°C in 50 μl of the recommended
buffers. The digested DNA was recovered by standard
ethanol precipitation and dissolved in 10 μlo fT E
(10 mM Tris-HCl (pH 8.0), 1 mM EDTA). Note that
the amount of DNA used for digestion is dependent
on the number of amplicons to be tested. For smaller
amount of DNA, use of appropriate carriers would be
helpful to ensure efficient recovery.
The DNA digested with each enzyme was then ampli-
fied using GenomiPhi Amplification Kit (GE Health-
care). We routinely use 50 ng of digested DNA for each
amplification. Briefly, 1 μl (50 ng) of digested DNA pre-
p a r e da sa b o v ew a sm i x e dw i t h9μl of sample buffer
and then denatured for 5 min at 96°C. Following cooling
down to 4°C, the denatured DNA was mixed with 9 μl
of reaction buffer and 1 μl of phi29 DNA polymerase,
and then incubated for two days at 30°C. For inactiva-
tion of phi29 DNA polymerase, the amplified DNA solu-
tion was heated for 10 min at 65°C. The amplified DNA
was purified by ethanol precipitation and dissolved in
100 μlo fT E .H e r e ,~ 5μg of whole-genome-amplified
DNA was obtained from 50 ng of digested DNA.
We used 1 μl (50 ng) of each WGA product prepared
as above for each PCR in 10 μlo ft h er e c o m m e n d e d
buffers containing 2.5 U of Ex-Taq DNA polymerase
(TaKaRa) and 2.5 pmols of each primer. Since each
HM-PCR assay involves 4 PCR, HM-WGA-PCR uses
200 ng (= 50 ng × 4) of amplified DNA in total, which
is equivalent to 2 ng of original genomic DNA. Thermal
cycling parameters and primer sequences used in this
study are shown in Additional file 1: Supplemental
Table S1.
Bisulfite sequence analysis
Bisulfite sequencing was performed as described [8].
Thermal cycling parameters and primer sequences are
described in Additional file 1: Supplemental Table S1.
Results and discussion
HpaII-McrBC whole-genome-amplification PCR (HM-
WGA-PCR) uses two types of restriction enzyme. One
is either HpaII (CCGG) or HhaI (GCGC), which digests
unmethylated DNA, but not methylated DNA (i.e.,
methylation-sensitive enzymes). The other type is
McrBC (R
mCN40-80R
mC), which cuts methylated DNA,
but not unmethylated DNA (i.e., methylation-dependent
enzyme) [13]. In HM-WGA-PCR, genomic DNA is first
digested with either HpaII/HhaIo rMcrBC and then
subjected to whole-genome-amplification by phi29 DNA
polymerase [14], which can uniformly amplify genomic
DNA (Figure 1). Finally, PCR amplification of each
amplicon is conducted by using the two whole-genome-
amplified DNA samples as the templates (i.e., one from
HpaII/HhaI digestion and the other from McrBC diges-
tion) (Figure 1).
Note that each amplicon is selected to contain both
HpaII/HhaIa n dMcrBC sites. If an amplicon is bialleli-
cally methylated (i.e., complete methylation), it is ampli-
fied only from HpaII-digested genomic DNA, but not
from McrBC-digested DNA (Figure 1). Conversely, if an
amplicon escapes methylation biallelically (i.e., null
methylation), it is amplified only from McrBC-digested
DNA, but not from HpaII-digested DNA (Figure 1).
If an amplicon is composed of both methylated and
unmethylated alleles (i.e., composite methylation), it is
amplified from both templates, because HpaII/HhaI and
McrBC fail to digest methylated and unmethylated
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methylated on both alleles (i.e., incomplete methylation),
it is amplified from neither template, because both
enzymes digest both alleles (Figure 1). Accordingly, four
different allelic methylation patterns (i.e., complete, null,
composite, and incomplete methylation) can be clearly
discriminated as four distinct amplification patterns
(Figure 1).
HM-WGA-PCR is based on HM-PCR, which includes
only two steps in Figure 1, namely “Digestion” and “PCR”
[8]. A drawback of HM-PCR is that it requires 200 ng of
genomic DNA to analyze methylation in one amplicon;
50 ng each for HpaII-, McrBC-, MspI- and mock-diges-
tion, the latter two of which serve as controls. Therefore,
it is not suitable for a comprehensive analysis of methyla-
tion when the quantity of available genomic DNA is lim-
ited. In HM-WGA-PCR, we input 500 ng of genomic
DNA for each digestion and used 1/10th of the digested
DNA (i.e., 50 ng) for WGA, which likely yielded ~5 μgo f
amplified DNA. We confirmed that 1/100th or 50 ng of
the WGA product, which is equivalent to 0.5 ng of original
genomic DNA, is enough for each PCR.
Since HM-WGA-PCR is basically identical to HM-
PCR except for the WGA process, both methods should
provide the same results on the same amplicon. We
thus examined whether or not HM-WGA-PCR can dis-
tinguish between the four allelic methylation patterns as
clearly as HM-PCR. For this purpose, we used primer
pairs for eight CGIs on human chromosome 21q (#85,
#95, #100, #102, #106, #112, #120, and #142) as repre-
sentatives of the four allelic methylation patterns (Addi-
tional file 1: Supplemental Table S1). As shown in
Figure 2A~2D, HM-PCR and HM-WGA-PCR provided
the same patterns. In other words, both HM-PCR and








m m








PCR
Amplified HpaII-
digested DNA
Amplified McrBC-
digested DNA
Digestion
HpaII McrBC
Figure 1  Yamada et al.
m m
m m m m








Amplified 
HpaII-digested 
DNA
Amplified 
McrBC-digested 
DNA
WGA
















m m







 m m
m








m








m








m








Complete
methylation 
Composite
methylation 
Null
methylation
Incomplete
methylation 
Figure 1 Principles of the HpaII-McrBC whole-genome-amplification PCR (HM-WGA-PCR) method. The two parallel lines in the “Digestion”
panel indicate genomic amplicons from both alleles. The circled “m” indicates a methylated CpG dinucleotide. HpaII digests unmethylated
CCGG, but not methylated C
mCGG. In contrast, McrBC digests methylated R
mC40-80R
mC sequences, but not unmethylated RC40-80RC. Genomic
DNA is digested with HpaII and McrBC independently. Subsequently, an aliquot of each restriction-enzyme-digested DNA (50 ng) is subjected to
whole-genome-amplification (WGA) to yield 5 μg of whole-genome-amplified DNA. Using an aliquot of the amplified DNA (50 ng), the target
DNA region is PCR-amplified by the primer pair (dotted arrows). The PCR products from the HpaII/HhaI-digested and McrBC-digested DNA are
electrophoresed, stained with ethidium bromide, and visualized by UV illumination. If an amplicon is fully methylated (i.e., complete methylation),
it is digested by McrBC, but not by HpaII. Thus, it is amplified from the HpaII-digested and whole-genome-amplified DNA, but not from the
McrBC-digested and whole-genome-amplified DNA. By contrast, if an amplicon totally escapes methylation (i.e., null methylation), it is digested
by HpaII, but not by McrBC. Thus, it is amplified from McrBC-digested and whole-genome-amplified DNA, but not from HpaII-digested and
whole-genome-amplified DNA. If an amplicon contains both methylated and unmethylated alleles (i.e., composite methylation), it is amplified
from both whole-genome-amplified templates. If an amplicon is partially methylated on both alleles (i.e., incomplete methylation), it is amplified
from neither whole-genome-amplified template.
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Figure 2 Comparison of HM-PCR and HM-WGA-PCR results for eleven CGIs. Genomic DNA from peripheral blood leukocytes was digested
with Mock (lane 1), HpaII or HhaI (lane 2), MspI (lane 3), or McrBC (lane 4). The digested genomic DNA were used for PCR amplification either
directly (left; HM-PCR) or after whole-genome-amplification (right; HM-WGA-PCR) using primer pairs for the eight CGIs on chromosome 21 (A~D)
and three CGIs on chromosome 11 (E). Here, when HhaI-digested genomic DNA was used in lane 2, 1 ul of distilled water was used in lane 3 in
place of MspI-digested genomic DNA. PCR products were electrophoresed, stained with ethidium bromide, and visualized by UV illumination.
Results of bisulfite sequencing are shown for the eight CGIs on chromosome 21 (A~D). Open and closed circles indicate unmethylated and
methylated CpG dinucleotides, respectively. Each row of circles represents each sequenced clone of bisufite PCR products.
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#100 and #102, #112 and #142, #95 and #106, are modi-
fied by complete-, null-, composite-, and incomplete-
methylation, respectively. These results suggested that
HM-WGA-PCR can distinguish the four methylation
status patterns on CGIs as distinctly as HM-PCR.
To test the robustness of HM-WGA-PCR more rigor-
ously, we applied it to the 147 CGIs on human chromo-
some 21q that had been analyzed in our previous study
(Additional file 1: Supplemental Table S1). While we
previously analyzed 149 CGIs in total, we omitted CGIs
#103 and #75 from this study for the following reasons.
The former CGI lacks recognition sites for methylation-
sensitive restriction enzymes and hence cannot be ana-
lyzed by HM-PCR; it had been analyzed by bisulfite
sequencing in our previous study [8]. The latter CGI
was omitted, because updated reference sequence data
disproved the validity of the primers used for this CGI
in the previous study (data not shown) [8].
We applied HM-WGA-PCR to the 147 CGIs and suc-
cessfully amplified all of them, suggesting largely
unbiased amplification by WGA. Furthermore, in every
case of the 147 CGIs, allelic methylation status revealed
by HM-WGA-PCR was exactly the same as that
revealed by the HM-PCR; we thus achieved 100% con-
sistency between the two methods (data not shown).
Note that these HM-WGA-PCR assays consumed only
300 ng of genomic DNA, whereas our previous HM-
PCR study of the same 147 CGIs had required 30 μg.
We applied HM-WGA-PCR to several CGIs on other
chromosomes, including CGIs #160, #592, and #610 on
chromosome 11q (Figure 2E), and confirmed that the
results of HM-PCR and HM-WGA-PCR are consistent
in all the cases examined (data not shown). We also
confirmed that HM-WGA-PCR works well on placental
DNA to give consistent results with our previous HM-
PCR (data not shown).
Taken together, HM-WGA-PCR is much more effi-
cient than HM-PCR and retains comparable accuracy to
HM-PCR. It would thus provide a reliable alternative to
HM-PCR, when examining allelic methylation status
using a limited quantity of DNA.
Allelic methylation status can be also examined by
methods based on bisulfite conversion of unmethylated
cytosine (e.g., bisulfite sequencing, COBRA [15], and
methylation-specific PCR [16]). While these methods
as well as HM-WGA-PCR require a few ng of DNA for
each assay and are thus comparable in terms of the
amount of DNA required, each of them has its own
advantages and drawbacks. For instance, bisulfite
sequencing has single nucleotide resolution, but requires
tedious steps for sequencing and, often, cloning. By con-
trast, PCR-based methods are much easier to perform,
although their resolution is limited. Among the PCR
methods, amplicons for bisulfite-based ones are forced
to be short due to the effect of bisulfite-induced DNA
fragmentation, whereas those for HM-WGA-PCR are
free from such concern and can be much longer. On
the other hand, HM-WGA-PCR can interrogate only
the regions bearing both HpaII/HhaIa n dMcrBC sites,
whereas bisulfite-based PCR methods are free from such
restriction. Incomplete bisulfite-conversion leads to false
methylation signals in bisulfite-based methods, and
incomplete digestion leads to false-positive PCR signals
in HM-WGA-PCR. In anyway, HM-WGA-PCR comple-
ments bisulfite-based methods and would be a method
of choice in various applications for its simplicity.
Additional material
Additional file 1: Supplemental Table S1. The table indicates PCR
conditions and primer sequences used in this study.
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